← Back to Search
Abundant Expression Of TIM-3, LAG-3, PD-1 And PD-L1 As Immunotherapy Checkpoint Targets In Effusions Of Mesothelioma Patients
E. Marcq, J. Waele, J. V. Audenaerde, E. Lion, E. Santermans, N. Hens, P. Pauwels, J. Van Meerbeeck, E. Smits
Published 2017 · Medicine
Download PDFAnalyze on Scholarcy
Malignant pleural mesothelioma (MPM) is an aggressive cancer with an increasing incidence, poor prognosis and limited effective treatment options. Hence, new treatment strategies are warranted which include immune checkpoint blockade approaches with encouraging preliminary data. Research on the immunological aspects of the easily accessible mesothelioma microenvironment could identify prognostic and/or predictive biomarkers and provide useful insights for developing effective immunotherapy. In this context, we investigated the immune cell composition of effusions (pleural and ascites fluids) from 11 different chemotherapy-treated MPM patients. We used multicolor flow cytometry to describe different subsets of immune cells and their expression of immune checkpoint molecules TIM-3, LAG-3, PD-1 and PD-L1. We demonstrate a patient-dependent inter- and intraspecific variation comparing pleural and ascites fluids in immune cell composition and immune checkpoint expression. We found CD4+ and CD8+ T cells, B cells, macrophages, natural killer cells, dendritic cells and tumor cells in the fluids. To the best of our knowledge, we are the first to report TIM-3 and LAG-3 expression and we confirm PD-1 and PD-L1 expression on different MPM effusion-resident immune cells. Moreover, we identified two MPM effusion-related factors with clinical value: CD4+ T cells were significantly correlated with better response to chemotherapy, while the percentage of PD-L1+ podoplanin (PDPN)+ tumor cells is a significant prognostic factor for worse outcome. Our data provide a basis for more elaborate research on MPM effusion material in the context of treatment follow-up and prognostic biomarkers and the development of immune checkpoint-targeted immunotherapy.
This paper references
MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
Patrice Hémon (2011)
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L. Monney (2002)
The worldwide pandemic of asbestos-related diseases.
L. Stayner (2013)
Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients.
L. Lievense (2017)
Malignant pleural effusion: tumor-host interactions unleashed.
G. Stathopoulos (2012)
Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation
Shinji Takeuchi (2017)
CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
N. Yamada (2010)
LAG-3 in Cancer Immunotherapy.
Monica V. Goldberg (2011)
Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid
A. Scherpereel (2013)
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens
E. Baixeras (1992)
The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cells
C. Workman (2003)
Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD‐L1 and the PD‐L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD‐L1 Antibody Avelumab
Swati Khanna (2016)
B. Robinson (2005)
Podoplanin overexpression in human mesothelioma cell lines enhances the tumorigenic phenotype.
Ei Yamaki (2013)
CD4 T cells: fates, functions, and faults. Blood
J Zhu (2008)
The PD‐1 pathway in tolerance and autoimmunity
Loise M. Francisco (2010)
Dual Control of Antitumor CD8 T Cells through the Programmed Death-1/Programmed Death-Ligand 1 Pathway and Immunosuppressive CD4 T Cells: Regulation and Counterregulation1
A. Currie (2009)
Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage‐Mediated T Cell Suppression
L. Lievense (2016)
Malignant pleural effusion: from bench to bedside
I. Psallidas (2016)
New Roads Open Up for Implementing Immunotherapy in Mesothelioma
R. Cornelissen (2012)
B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
A. Mansfield (2014)
Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
S. Cedrés (2015)
Advances in malignant mesothelioma.
B. Robinson (2005)
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
Novel Targeted Therapies and Vaccination Strategies for Mesothelioma
M. Bagia (2011)
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
R. H. Thompson (2006)
Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)1
C. Workman (2005)
Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies.
V. Izzi (2012)
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
E. Alley (2017)
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.
R. Hassan (2016)
Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9.
M. Gleason (2012)
Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes
K. Friedman (2012)
Cisplatininduced antitumor immunomodulation: a review of preclinical and clinical evidence
AR de Biasi (2014)
Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients
J. Fourcade (2008)
Diagnostic Utility of Pleural Fluid Cell Block versus Pleural Biopsy Collected by Flex-Rigid Pleuroscopy for Malignant Pleural Disease: A Single Center Retrospective Analysis
Shion Miyoshi (2016)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
J. Hamanishi (2007)
Podoplanin is a useful marker for identifying mesothelioma in malignant effusions
Atef N Hanna (2010)
Promotion of Tissue Inflammation by the Immune Receptor Tim-3 Expressed on Innate Immune Cells
A. Anderson (2007)
Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages
Anne-Laure Chéné (2016)
CD4 T cells: fates, functions, and faults.
J. Zhu (2008)
The negative regulatory function of the lymphocyte‐activation gene‐3 co‐receptor (CD223) on human T cells
L. Maçon-Lemaître (2005)
Targeting immune checkpoints: New opportunity for mesothelioma treatment?
E. Marcq (2015)
Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma
E. Marcq (2017)
Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma
R. Hino (2010)
Randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment of unresectable pleural or peritoneal mesothelioma.
M. Maio (2014)
Improved Endpoints for Cancer Immunotherapy Trials
A. Hoos (2010)
Microenvironment and Immunology Anti-TIM 3 Antibody Promotes T Cell IFN-g – Mediated Antitumor Immunity and Suppresses Established Tumors
S. Ngiow (2011)
A phase II study of Nivolumab in malignant pleural mesothelioma (NIVOMES): with translational research (TR) biopsies
JQ Janssen (2017)
Podoplanin as a marker for mesothelioma
Noriko Kimura (2005)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
The emerging role of T cell cytokines in non-small cell lung cancer.
M. Neurath (2012)
A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients.
L. Calabrò (2014)
Malignant mesothelioma. The university of minnesota experience
N. Vogelzang (1984)
This paper is referenced by
Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma.
I. C. Salaroglio (2019)
Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives.
S. Gray (2020)
Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma
Svenja Wagener-Ryczek (2020)
Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer
Lukas W. Pfannenstiel (2019)
The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy
L. Long (2018)
Making cold malignant pleural effusions hot: driving novel immunotherapies
Pranav Murthy (2019)
The hallmarks of successful anticancer immunotherapy
L. Galluzzi (2018)
Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting
Fabio Nicolini (2020)
Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors
Jonathan Chee (2018)
The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
G. Chu (2019)
Immunotherapy for mesothelioma: rationale and new approaches.
Joshua E Reuss (2020)
FFPE Formalin-fixed and paraffin embedded FLOT FLOT-trial regimen with 5FU, Folinic acid, Oxaliplatin, Docetaxel H&E Hematoxylin–eosin HAVCR2 Hepatitis A virus cellular receptor 2 HER2 Human epidermal growth factor receptor 2 HLA Human histocompatibility leukocyte Ag IDO Indoleamine-pyrrole
NK‐ and T‐cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti‐CTLA‐4 therapy
Rosa Sottile (2019)
Engineering CAR-T Cells for Improved Function Against Solid Tumors
M. Morgan (2018)
Microenvironment and Immunology of the Human Pleural Malignant Mesothelioma
Elisabeth Digifico (2019)
PTPN3 expressed in activated T lymphocytes is a candidate for a non-antibody-type immune checkpoint inhibitor
A. Fujimura (2019)